Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID-19 therapeutic- CEL-SCI Corporation

Drug Profile

COVID-19 therapeutic- CEL-SCI Corporation

Latest Information Update: 31 Mar 2020

At a glance

  • Originator CEL-SCI Corporation
  • Class Antivirals; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 26 Mar 2020 CEL-SCI Corporation entered into a collaboration agreement with the University of for the development of Coronavirus vaccine
  • 09 Mar 2020 Early research in COVID-2019 infections in USA (unspecified route)

Development Overview


An immunotherapy directed towards antigens within the NP protein of COVID-19 is being developed by CEL-SCI Corporation for the treatment of coronavirus infection. The therapeutic is being developed using the company's proprietary L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology platform which will use conserved regions of coronavirus proteins to stimulate protective cell mediated cytolytic T cell responses and reduce viral load. L.E.A.P.S.™ generated therapeutics exhibit both antiviral and anti-inflammatory properties. The COVID-19 peptide is believed to not only arrest the progression of the virus but also prevent tissue damage from inflammation resulting from lung infection by the virus. Early research is ongoing in the US.

Company Agreements

In March 2020, CEL-SCI Corporation entered into a collaboration agreement with the University of Georgia’s Center for Vaccines and Immunology for the development of LEAPS COVID-19 immunotherapy. The collaboration will commence with pre-clinical studies based on the experiments previously conducted with LEAPS immunotherapy in collaboration with the National Institutes for Allergies and Infectious Diseases (NIAID) against another respiratory virus, H1N1, involved in the 2009 H1N1 flu pandemic. [1]

Patent Information

L.E.A.P.S.™ is protected by patents in the United States issued in February 2006, April 2007, August 2007, January 2019 and March 2019. The LEAPS patents, which expire in 2021, 2022, 2021 and three in 2032, respectively, include overlapping claims, with composition of both matter (new chemical entity), process and methods-of-use, to maximize and extend the coverage in their current format [2] [3] [4] .

In October 2017, a patent was issued in Europe for L.E.A.P.S.™ , which expires in 2029 [2] .

CEL-SCI Corporation has four patent applications pending in the United States and one in Europe for L.E.A.P.S.™, which, if issued, would extend protection through 2034, subject to any potential patent term extensions [2] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Antivirals, Peptides
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J05A-X (Other antivirals)

  • EPhMRA code

    J5B9 (Antivirals, others)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research USA unspecified / unspecified CEL-SCI Corporation 09 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
CEL-SCI Corporation Originator USA
CEL-SCI Corporation Owner USA
University of Georgia Collaborator USA

Development History

Event Date Update Type Comment
26 Mar 2020 Licensing Status CEL-SCI Corporation entered into a collaboration agreement with the University of for the development of Coronavirus vaccine [1] Updated 31 Mar 2020
09 Mar 2020 Phase Change Early research in COVID-2019 infections in USA (unspecified route) Updated 20 Mar 2020
23 Dec 2019 Patent Information CEL-SCI has patents pending for LEAPS technology in USA and European Union [2] Updated 20 Mar 2020
30 Jan 2018 Patent Information CEL-SCI has patent protection for LEAPS technology in USA and in European Union [3] Updated 20 Mar 2020


  1. CEL-SCI to Develop LEAPS COVID-19 Immunotherapy in Collaboration with University of Georgia Center for Vaccines and Immunology.

    Media Release
  2. CEL SCI Corporation SEC filing, December 2019. Internet-Doc 2020;.

    Available from: URL: http://filings.irdirect.net/data/725363/000165495419014164/cvm_10kn.pdf

    Media Release
  4. U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology.

    Media Release
Back to top